Search Result

Results for "

surgery

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Antibiotic (1) Autophagy (1) Bacterial (2) COX (1) Fluorescent Dye (3) GHSR (1) Isotope-Labeled Compounds (1) nAChR (2) Phospholipase (1) PSMA (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (2) Infection (2) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (5)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-106887

SCH 32615	Others	Neurological Disease
SCH 32615 is an enkephalinase (the enzymes responsible for the degradation of endogenous enkephalins) inhibitor. SCH 32615 can enhance surgery- and pregnancy-induced analgesia in mice .

HY-B0002A

Ondansetron hydrochloride dihydrate 5+ Cited Publications GR 38032 hydrochloride dihydrate; SN 307 hydrochloride dihydrate	5-HT Receptor	Neurological Disease
Ondansetron (GR 38032) hydrochloride dehydrate is an orally active, highly selective and competitive 5-HT₃ receptor antagonist (crosses the blood-brain barrier). Ondansetron hydrochloride dehydrate can be used in studies of preventing nausea and vomiting associated with cancer chemotherapy, radiation therapy and surgery .

HY-108298

Perfluorodecalin PP 5; Perfluorodecahydronaphthalene	Others	Others
Perfluorodecalin liquids are largrly used in vitreoretinal surgery. Perfluorodecalin with tamponade lasting more than two days is detrimental to the retina in the case of rabbit. Perfluorodecalin can be used for the research of giant retinal tears . Perfluorodecalin is a non-toxic, non-flammable, thermally stable, non-bio-accumulating O₂-carrier and used as artificial blood . Perfluorodecalin enhances bone regeneration and cell viability .

HY-B1372

Tribromoethyl alcohol 5+ Cited Publications 2,2,2-Tribromoethanol; Narcolan	Others	Neurological Disease
Tribromoethyl alcohol (2,2,2-Tribromoethanol) is used to animals, particularly rodents, before surgery.

HY-111232

GSK894281	GHSR	Metabolic Disease
GSK894281 is an orally active and highly potent ghrelin receptor full agonist with a pEC₅₀ of <4.9 at the human motilin receptor. GSK894281 effectively enters the CNS. GSK894281 has the potential for constipation or to assist in emptying the colon prior to colonoscopy or colon surgery research .

HY-E70225

Hemocoagulase, deinagkistrodonacutus	Others	Others
Hemocoagulase, deinagkistrodonacutus is a hemocoagulase isolated and purified from the venom of agkistrodon agkistrodon to prevent bleeding after surgery .

HY-17569

Difluprednate	Phospholipase	Inflammation/Immunology
Difluprednate is a topical corticosteroid, which is thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). Difluprednate is used for the symptomatic treatment of inflammation and pain associated with ocular surgery.

HY-148796

Rizedisben GE3126	Fluorescent Dye	Others
Rizedisben (GE3126) is a fluorophore that can be used in fluorescence image-guided surgery. Rizedisben reduces non-specific adipose tissue fluorescence intensity and enhances nerve visibility .

HY-B1248

Chlorhexidine 5+ Cited Publications	Bacterial Antibiotic	Infection Cancer
Chlorhexidine is an antibacterial used as an antiseptic and for other applications. Chlorhexidine is used to clean the skin after an injury, before surgery, or before an injection. Chlorhexidine is also used to clean the hands before a procedure .

HY-B1248A

Chlorhexidine acetate hydrate	Bacterial	Infection Cancer
Chlorhexidine acetate hydrate is an antibacterial used as an antiseptic and for other applications. Chlorhexidine acetate hydrate is used to clean the skin after an injury, before surgery, or before an injection. Chlorhexidine acetate hydrate is also used to clean the hands before a procedure .

HY-17440

Rocuronium Bromide 2 Publications Verification ORG 9426 Bromide	nAChR	Neurological Disease Cancer
Rocuronium Bromide (ORG 9426 Bromide) is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal musclerelaxation during surgery or mechanical ventilation.

HY-149298

PSMA-IN-2	PSMA	Cancer
PSMA-IN-2 is an inhibitor of PSMA with a K_i value of 1.07 nM. PSMA-IN-2 displays favorable in vivo NIR imaging (λ_EM = 1088 nm, λ_ex = 808 nm), and can be used for NIRII image-guided tumor resection surgery in PSMA-positive tumor-bearing mice .

HY-D1905

ICG acid	Fluorescent Dye	Cancer
ICG acid is a fluorescent dye used in medical diagnostics. ICG acid has absorption peaking at 800 nm and can absorb the near IR laser energy and release heat in the dyed tissue. ICG acid has been used in fluorescence-guided surgery to identify critical structures, including intra-abdominal tumors .

HY-17440R

Rocuronium Bromide (Standard) ORG 9426 Bromide (Standard)	nAChR	Neurological Disease Cancer
Rocuronium (Bromide) (Standard) is the analytical standard of Rocuronium (Bromide). This product is intended for research and analytical applications. Rocuronium Bromide (ORG 9426 Bromide) is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal musclerelaxation during surgery or mechanical ventilation.

HY-14252A

Milrinone lactate Win 47203 lactate	Others	Cardiovascular Disease
Milrinone lactate is a potent inotropic dilating agent. Milrinone lactate shows simultaneous positive inotropic and vasodilating activities. Milrinone lactate promotes reduction of SVR and PVR in patients with DCM and NYHA class III and IV of heart failure. Milrinone lactate has the potential for the research of cardiovascular function after cardiac surgery and in septic shock .

HY-B1888AS

Bromfenac-d4 sodium	Isotope-Labeled Compounds COX	Inflammation/Immunology
Bromfenac-d₄ (sodium) is deuterium labeled Bromfenac (sodium). Bromfenac sodium is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac sodium is a brominated non-steroidal anti-inflammatory/analgesic agent (NSAID), and it is commonly used for the research of postoperative inflammation and pain following cataract surgery, and pseudophakic cystoid macular edema (CME)[1][2].

HY-A0119

Nitroprusside disodium dihydrate 4 Publications Verification Sodium nitroprusside dihydrate; Sodium Nitroferricyanide(III) Dihydrate	Autophagy	Cardiovascular Disease Cancer
Nitroprusside disodium dehydrate (Sodium nitroprusside dihydrate) is a vasodilator that available for the research of acute hypertension, heart failure. Nitroprusside disodium dehydrate induces autophagy in glutathione-depleted osteoblasts. Nitroprusside disodium dehydrate acts as a nitric oxide (NO) donor in a rat intestinal ischemia reperfusion model .

HY-W110929

Patent Blue V Acid blue 1	Fluorescent Dye	Cancer
Patent Blue V (Acid blue 1) is a novel biological dye that can be used as an intraocular dye for retinectomy. Retinectomy refers to the removal of the translucent inner limiting membrane (ILM). The application of appropriate dyes in vitreoretinal surgery can achieve the purpose of complete removal. Patent Blue V can be used to stain retinal premembranous structures. Spectral analysis shows that Patent Blue V has strong absorption below 450 nm and above 600 nm, showing a blue-green color. Patent Blue V is also used as a marker in lymphangiography for resection of neoplastic lymph nodes .

HY-B2091

Azidocillin
Azidocillin, a semi-synthetic Penicillin, is an orally active β-lactam antibiotic. Azidocillin bears an azide functionality and retains on-target activity within bacteria. Azidocillin can be used to research osteitis caused by dental surgery, otitis media, enterococcal septicemia and other bacterial infectious diseases . Azidocillin is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

Cat. No.	Product Name

HY-L112

Chemotherapy Drug Library	100 compounds
Chemotherapy is one of the most common treatments for cancer. It can be used alone for some types of cancer or in combination with other treatments such as radiation or surgery. Chemotherapy drugs usually target cells at different phases of the cell cycle and inhibit tumor proliferation and avoid cancer cell invasion and metastasis. It is a cancer treatment method that kills cancer cells with drugs. Chemotherapeutic agents can be classified into alkylating agents, antimetabolites, antimicrotubular agents, antibiotics, etc. according to the mechanism of action. MCE offers a unique collection of 100 chemotherapy drugs, which is a useful tool for cancer treatment research.

Chemotherapy Drug Library

100 compounds

Chemotherapy is one of the most common treatments for cancer. It can be used alone for some types of cancer or in combination with other treatments such as radiation or surgery. Chemotherapy drugs usually target cells at different phases of the cell cycle and inhibit tumor proliferation and avoid cancer cell invasion and metastasis. It is a cancer treatment method that kills cancer cells with drugs.

Chemotherapeutic agents can be classified into alkylating agents, antimetabolites, antimicrotubular agents, antibiotics, etc. according to the mechanism of action. MCE offers a unique collection of 100 chemotherapy drugs, which is a useful tool for cancer treatment research.

HY-L173

Anti-Ovarian Cancer Compound Library	1883 Compounds compounds
Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer. MCE designs a unique collection of 1883 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

Anti-Ovarian Cancer Compound Library

1883 Compounds compounds

Ovarian cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate and poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors and sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread and drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.

MCE designs a unique collection of 1883 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR and HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development and research of anti-ovarian compounds.

HY-L075

Anti-Lung Cancer Compound Library	1835 compounds
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers. As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy. MCE offers a unique collection of 1835 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

Anti-Lung Cancer Compound Library

1835 compounds

Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.

As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.

MCE offers a unique collection of 1835 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.

HY-L074

Anti-Breast Cancer Compound Library	1953 compounds
Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC). Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer. MCE supplies a unique collection of 1953 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

Anti-Breast Cancer Compound Library

1953 compounds

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 1953 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

ICG acid	Fluorescent Dyes/Probes
ICG acid is a fluorescent dye used in medical diagnostics. ICG acid has absorption peaking at 800 nm and can absorb the near IR laser energy and release heat in the dyed tissue. ICG acid has been used in fluorescence-guided surgery to identify critical structures, including intra-abdominal tumors .

Patent Blue V Acid blue 1	Biochemical Assay Reagents
Patent Blue V (Acid blue 1) is a novel biological dye that can be used as an intraocular dye for retinectomy. Retinectomy refers to the removal of the translucent inner limiting membrane (ILM). The application of appropriate dyes in vitreoretinal surgery can achieve the purpose of complete removal. Patent Blue V can be used to stain retinal premembranous structures. Spectral analysis shows that Patent Blue V has strong absorption below 450 nm and above 600 nm, showing a blue-green color. Patent Blue V is also used as a marker in lymphangiography for resection of neoplastic lymph nodes .

Bromfenac-d4 sodium
Bromfenac-d₄ (sodium) is deuterium labeled Bromfenac (sodium). Bromfenac sodium is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac sodium is a brominated non-steroidal anti-inflammatory/analgesic agent (NSAID), and it is commonly used for the research of postoperative inflammation and pain following cataract surgery, and pseudophakic cystoid macular edema (CME)[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.